The oral GLP-2 tablet program combines a proprietary long acting GLP-2 agonist developed by OPKO with Entera’s proprietary N-Tab™ technology for patients suffering from short bowel syndrome and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback